ABAdela-Georgiana Buciuc

Adela-Georgiana Buciuc

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Adela-Georgiana Buciuc has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Psychedelics and Psychedelic-Inspired Compounds for Substance Use Disorders: Are We Treating the Disease or Opening a Learning Window?

    by Adela G. Buciuc, Mark S. Gold, Brian Fuehrlein

    Substance use disorders remain a leading cause of preventable death, and existing care is better described as disease management than as cure. Medications for opioid, alcohol, and tobacco use disorders reduce substance use, and opioid agonist treatment reduces mortality, yet retention is poor and functional recovery is rarely measured. This review asks whether psychedelics treat addiction, or temporarily create a brain state in which treatment, learning, and recovery work differently. By evaluating each pharmacologically unique compound individually, we align cellular mechanisms, animal studies and human trial data across the full spectrum of substance use disorders. Relapse prevention is not a single construct: conditioned place preference, operant reinstatement, extinction learning, and clinical abstinence index different processes, and agreement at one level does not imply agreement at another. Translational concordance is therefore indication- and compound-specific rather than a class property, with the strongest human signals for psilocybin in tobacco and alcohol use disorders, though even the alcohol signal rests on two small randomized trials with discordant results. Risk is compound-specific too: ibogaine is gated by cardiotoxicity, and ketamine carries reinforcing properties and organ toxicity of its own. Plasticity is an opportunity, not an outcome.

  • Open Access

    Glucagon-like Peptide-1 Receptor Agonists for Substance Use Disorders: Comprehensive Review of Circuit Mechanisms and Clinical Evidence

    by Adela G. Buciuc, Mark S. Gold, Brian Fuehrlein

    Substance use disorders (SUDs) are a leading cause of preventable death worldwide, yet approved pharmacotherapies exist for only three of them: alcohol, tobacco, and opioid use disorders. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), established in metabolic medicine, are candidates for repurposing across multiple SUDs. This review synthesizes preclinical mechanistic evidence, pharmacoepidemiologic data, and randomized trials, comprehensively for human studies and selectively for preclinical work establishing circuit-level mechanisms. GLP-1 RAs attenuate the peak amplitude and frequency of drug-evoked dopamine release in the nucleus accumbens through shared mesolimbic mechanisms while engaging substance-specific circuits, including the lateral septum for alcohol and psychostimulants and the medial habenula–interpeduncular pathway for nicotine. Evidence from CB1–incretin interaction studies suggests a distinct rationale for cannabis use disorder, in which GLP-1 RA administration may correct a drug-induced suppression of incretin tone; this framing is theoretical and has not been tested against addiction endpoints. Clinical evidence is most robust for alcohol use disorder, where convergent pharmacoepidemiologic signals and the SEMALCO randomized trial demonstrate efficacy in individuals with comorbid obesity; data for opioid, tobacco, cocaine, and cannabis use disorders remain limited. Translational barriers include dose–response relationships that remain uncharacterized because no trial has performed dose-ranging against an addiction endpoint, safety concerns in patients with eating pathology, and metabolic phenotype as a moderator, with directionally opposite effects across body mass index strata. Whether GLP-1 RAs achieve transdiagnostic utility will likely depend on patient selection and agent choice, but no validated selection criteria exist and this remains a hypothesis to be tested.

  • Retrospective chart review on psychiatric manifestations of GLP-1 agonist usage

    by Brianna Sa, Anthony Maristany, Ashwin Subramaniam, Nayha Kumbkarni, Rachel Lange, Sean Oldak, Adela-Georgiana Buciuc, Vanessa Padilla


  • Open Access

    Use of Long-Acting Injectables for Severe Mental Illness in the Peripartum Period: A Case Report and a Scoping Review

    by Adela-Georgiana Buciuc, Sean E Oldak, Edmi Y Cortes

    The management of acute mania during pregnancy poses a complex clinical task, necessitating careful consideration of treatment options and demanding a delicate balance between the risks associated with medication use and the adverse impacts of untreated severe mental illness on the fetus. Medication nonadherence stands out as a significant factor contributing to relapse, with rates potentially reaching 40%. The pharmacokinetic profile of long-acting injectable (LAI) risperidone contrasts with that of oral risperidone, characterized by a gradual and consistent release from the depot, mitigating fluctuations between peak and trough concentrations. Clinically, this sustained plasma profile of LAI risperidone has been linked to a reduction in adverse events, such as extrapyramidal side effects, metabolic syndrome, and hyperprolactinemia. Numerous studies have indicated that LAI antipsychotic therapy correlates with reduced mortality rates and decreased number of hospitalizations. This case report illustrates the effective management of acute mania in a pregnant 32-year-old through the utilization of LAI risperidone. This case underscores the significance of individualized treatment strategies and emphasizes the potential utility of LAI antipsychotics as a viable therapeutic option for managing acute mania in pregnancy. Further research is warranted to delineate the long-term outcomes and safety profile of LAI antipsychotics in this population.

  • Open Access

    An Unusual Presentation of Serotonin Syndrome and Subsequent Catatonia in a Patient With a Family History of Huntington’s Disease

    by Paula Traugott, Carlos R. Danger, Adela-Georgiana Buciuc

    Neuroleptic malignant syndrome (NMS) and serotonin syndrome (SS) represent serious life-threatening conditions that share phenotypic and pathophysiologic features due to intricate interactions between the dopaminergic and serotoninergic systems. Malignant catatonia’s underlying pathophysiological mechanisms are poorly understood, but it is clinically difficult to distinguish it from NMS. Huntington’s disease (HD) is an autosomal dominant neurodegenerative disorder characterized by CAG expansion in exon 1 of the huntingtin (HTT) gene. Even though involuntary movements and lack of coordination are pivotal in HD, psychiatric manifestations are an integral part of it and may precede the emergence of chorea by years. The overlap in symptoms is noticeable for SS and NMS and distinguishing between the two may be challenging if exposure to both dopamine antagonists and serotoninergic agents exists. We present the case of a 48-year-old woman with an unusual presentation of serotonin syndrome and subsequent catatonia possibly overlapping with a neurodegenerative disorder, HD. This case report offers an interesting interconnection between three different syndromes that have tight pathophysiological and phenotypical associations.